Pharma BD Deal Intelligence
AstraZeneca and Ionis signed a deal to develop and commercialize eplontersen, with AstraZeneca paying $200 million upfront and up to $485 million in…
Wainua (eplontersen) granted first-ever regulatory approval in the US for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
AstraZeneca and Ionis Pharmaceuticals entered a global development and commercialization agreement for eplontersen, Ionis' LIgand-Conjugated Antisense (LICA) medicine that inhibits production of transthyretin (TTR) protein for the treatment of transthyretin amyloidosis (ATTR). Under the terms, Ionis received a $200 million upfront payment, was eligible for up to $485 million in development and approval milestones and up to $2.9 billion in sales-related milestones, plus tiered royalties ranging from low double-digit to mid-20s percent depending on region. The companies jointly develop and commercialize eplontersen in the U.S., while AstraZeneca holds exclusive rights to commercialize in the rest of the world. Hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN) was the first indication: eplontersen was approved by the U.S. FDA on December 21, 2023 under the brand name Wainua, the only ATTRv-PN treatment that can be self-administered via auto-injector. The drug is also being evaluated in the Phase 3 CARDIO-TTRansform study (>1,400 patients) for the much larger ATTR cardiomyopathy (ATTR-CM) indication, with topline data expected in the second half of 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / Ionis Pharmaceuticals, Inc. (this deal) | 2021 | $4.2B | 73 |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
| AstraZeneca PLC / CinCor Pharma Inc. | 2023 | $1.8B | 78 |
← Browse all deals · How we score deals
More: 2021 deals · AstraZeneca PLC deals · Cardiovascular deals